Saturday 17 October 2026
Export CYTK’s income statement to Excel — free account
Cytokinetics, Incorporated
CYTK Healthcare Biotechnology
Cytokinetics, Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $88.0 million, up 376.6% from fiscal 2024. In the quarter to June 2026, revenue fell 57.1%, EPS fell 33.9%, free cash flow fell 24.0% and total debt rose 57.7%, each against the same quarter a year earlier.
61.95
1.97
−3.08%
Follow CYTK
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
75.61 | 86.68 | 76.78 | 166.28 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(61.34) | (53.50) | (55.86) | (70.40) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
77.03 | 89.80 | 80.04 | 166.01 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(15.52) | (15.50) | (16.17) | (20.22) | |
EV/FCF |
(14.82) | (14.78) | (15.43) | (19.34) | |
Quick Ratio |
6.78 | 4.45 | 4.14 | 6.56 | |
Current Ratio |
6.88 | 4.53 | 4.21 | 6.66 | |
Net Debt/EBITDA |
(0.75) | (1.57) | (1.91) | 0.11 | |
Debt/Assets |
75.61% | 81.23% | 91.29% | 59.60% | |
Debt/Equity |
(2.08) | (1.75) | (1.41) | (6.61) | |
Asset Turnover |
0.06 | 0.06 | 0.08 | 0.04 | |
Operating CF/Net income |
0.35 | 0.78 | 0.71 | 0.80 | |
Capex/Depreciation |
(3.49) | (1.97) | (1.76) | (1.19) | |
Interest Coverage |
(6.34) | (5.88) | (5.51) | (5.14) | |
Research and Development Expense of Revenue |
5,125.67% | 610.49% | 493.54% | 341.70% | |
Selling, General and Administrative Expense of Revenue |
3,587.71% | 516.60% | 541.96% | 364.72% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
1,585.54% | 171.82% | 157.03% | 124.76% | |
Graham Net Nets |
(0.15) | (0.15) | (0.16) | (0.08) | |
Graham Number |
24.79 | 28.41 | 32.12 | 14.61 | |
Earnings Yield |
(11.44%) | (10.28%) | (10.38%) | (8.48%) | |
Free Cash Flow Yield |
(6.88%) | (7.01%) | (6.76%) | (5.16%) | |
Revenue per Share |
0.02 | 0.15 | 0.16 | 0.22 | |
Operating CF per Share |
(0.90) | (1.19) | (1.18) | (1.21) | |
Capex per Share |
(0.08) | (0.05) | (0.05) | (0.03) | |
Free Cash Flow per Share |
(0.97) | (1.23) | (1.23) | (1.24) | |
Cash per Share |
8.02 | 7.35 | 6.64 | 8.83 | |
Shareholders Equity per Share |
(4.34) | (5.49) | (6.71) | (1.31) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(4.34) | (5.49) | (6.71) | (1.31) | |
Free Cash Flow |
(116.86) | (148.29) | (151.39) | (164.17) | |
Working Capital |
835.21 | 714.52 | 640.28 | 1,027.06 | |
Capital Expenditures |
(9.35) | (5.64) | (5.93) | (4.33) | |
Net Current Asset Value |
(980.33) | (1,167.19) | (1,260.58) | (889.55) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
4.83 | 0.32 | 0.31 | 0.15 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
1.03 | 17.21 | 4.42 | 16.42 | |
Average Payables |
16.83 | 21.35 | 19.33 | 18.37 | |
Average Assets |
1,436.31 | 1,413.11 | 1,268.76 | 1,575.09 | |
Average Common Equity |
(267.52) | (397.50) | (546.49) | (271.10) |
Columns are period end dates